

**16 February 2022**

**Cizzle Biotechnology Holdings Plc**

("Cizzle Biotechnology", "Cizzle" or the "Company")

**Total Voting Rights**

Cizzle Biotechnology, the UK based diagnostics developer, announces a correction to the total voting rights section of the Company's announcement made on 14 February 2022 where the nominal value of the Cizzle Biotechnology ordinary shares was incorrectly stated. The correct wording is set out below.

Following admission of the 25,000,000 Initial Consideration new Ordinary Shares to trading on the Standard Segment of the Official List and the Main Market of the London Stock Exchange ("Admission"), which is expected to become effective on 17 February 2022, the Company's issued ordinary share capital will consist of 278,447,788 ordinary shares of 0.01 pence each, all with voting rights. The Company holds no ordinary shares in Treasury. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

All terms in this announcement not defined herein carry the same meaning as in the Company's announcement made on 14 February 2022.

**Enquiries:**

**Cizzle Biotechnology Holdings plc**  
Allan Syms (Executive Chairman)

**Via IFC Advisory**

**Allenby Capital Limited**  
John Depasquale  
Alex Brearley

**+44(0) 20 33285656**

**Novum Securities Limited**  
Colin Rowbury  
Jon Bellis

**+44(0) 20 7399 9400**

**IFC Advisory Limited**  
Tim Metcalfe  
Florence Chandler

**+44(0) 20 3934 6630**  
**cizzle@investor-focus.co.uk**

**Notes to Editors:**

**About Cizzle Biotechnology**

Cizzle Biotechnology is developing a blood test for the early detection of lung cancer. Cizzle Biotechnology is a spin- out from the University of York, founded in 2006 around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer.

For more information, please see <https://cizzlebiotechnology.com>

You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.